Alimera Sciences Cash Over Time
| ALIM Stock | USD 3.12 0.22 7.59% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Alimera Sciences Performance and Alimera Sciences Correlation. Alimera |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alimera Sciences. If investors know Alimera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alimera Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.25) | Revenue Per Share 2.413 | Quarterly Revenue Growth 0.699 | Return On Assets (0.01) | Return On Equity (1.97) |
The market value of Alimera Sciences is measured differently than its book value, which is the value of Alimera that is recorded on the company's balance sheet. Investors also form their own opinion of Alimera Sciences' value that differs from its market value or its book value, called intrinsic value, which is Alimera Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alimera Sciences' market value can be influenced by many factors that don't directly affect Alimera Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alimera Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alimera Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alimera Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Cash Analysis
Compare Alimera Sciences and related stocks such as Aldeyra, Travere Therapeutics, and Connect Biopharma Cash Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALDX | 251 K | 251 K | 1.2 M | 3.3 M | 8.5 M | 14.6 M | 12 M | 20 M | 47.4 M | 44.4 M | 77.9 M | 229.8 M | 144.4 M | 142.8 M | 150 M |
| TVTX | 4.8 K | 3.9 K | 11.4 K | 6 M | 18.2 M | 37.8 M | 41 M | 99.4 M | 102.9 M | 62.4 M | 84.8 M | 165.8 M | 61.7 M | 58.2 M | 58 M |
| CNTB | 309 M | 309 M | 309 M | 309 M | 309 M | 309 M | 309 M | 309 M | 309 M | 309 M | 1 B | 1.7 B | 550.3 M | 106 M | 100.7 M |
| ABOS | 6.6 M | 6.6 M | 6.6 M | 6.6 M | 6.6 M | 6.6 M | 6.6 M | 6.6 M | 6.6 M | 6.6 M | 43.8 M | 122.2 M | 130.1 M | 66.9 M | 81.3 M |
| NUVB | 3.5 M | 3.5 M | 3.5 M | 3.5 M | 3.5 M | 3.5 M | 3.5 M | 3.5 M | 3.5 M | 3.5 M | 29.8 M | 132.4 M | 101.1 M | 42.6 M | 68.1 M |
| ELDN | 11.7 M | 11.7 M | 11.7 M | 31.8 M | 105.3 M | 24 M | 23.2 M | 17.2 M | 13 M | 8.8 M | 114.2 M | 84.8 M | 56.4 M | 4.6 M | 4.4 M |
| OPT | 19.5 K | 17 M | 9.3 M | 6.7 M | 14.1 M | 10.8 M | 39.9 M | 23.9 M | 10.6 M | 29.6 M | 118.2 M | 44.6 M | 89.2 M | 102.6 M | 107.7 M |
| CNTA | 7.2 M | 7.2 M | 7.2 M | 7.2 M | 7.2 M | 7.2 M | 7.2 M | 7.2 M | 7.2 M | 7.2 M | 7.2 M | 595.1 M | 393.6 M | 128 M | 121.6 M |
| NUVL | 3 M | 3 M | 3 M | 3 M | 3 M | 3 M | 3 M | 3 M | 3 M | 3 M | 10.3 M | 68.5 M | 241.8 M | 335.4 M | 352.2 M |
Alimera Sciences and related stocks such as Aldeyra, Travere Therapeutics, and Connect Biopharma Cash description
Cash refers to the most liquid asset of Alimera Sciences, which is listed under current asset account on Alimera Sciences balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Alimera Sciences customers. The amounts must be unrestricted with restricted cash listed in a different Alimera Sciences account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.My Equities
My Current Equities and Potential Positions
| Alimera Sciences | ALIM |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Georgia; U.S.A |
| Exchange | NASDAQ Exchange |
USD 3.12
Additional Information and Resources on Investing in Alimera Stock
When determining whether Alimera Sciences is a strong investment it is important to analyze Alimera Sciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Alimera Sciences' future performance. For an informed investment choice regarding Alimera Stock, refer to the following important reports:Check out Alimera Sciences Performance and Alimera Sciences Correlation. To learn how to invest in Alimera Stock, please use our How to Invest in Alimera Sciences guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Alimera Sciences technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.